CS
ACRS icon

Candriam SCA’s Aclaris Therapeutics ACRS Stock Holding History

Candriam SCA’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-55,208
Closed -$411K – 715
2023
Q1 		$411K Sell
55,208
-3,439
-6% -$43.6K ﹤0.01% 818
2022
Q4 		$924K Buy
58,647
+2,368
+4% +$38.1K 0.01% 713
2022
Q3 		$886K Buy
+56,279
New +$887K 0.01% 732

Other funds holding ACRS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Candriam SCA's ACRS Position: Q2 2023 in Review

Candriam SCA sold out of Aclaris Therapeutics (ACRS) in Q2 2023, closing a stake of 55,208 shares — an estimated $411K sold.

Candriam SCA first reported a position in ACRS in Q3 2022 and held it in 3 quarters. The position peaked at $924K in Q4 2022. 133 funds tracked by Wall St. Rank hold ACRS as of Q2 2023.

  • Candriam SCA reported no remaining Aclaris Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Candriam SCA sold 55,208 Aclaris Therapeutics shares in Q2 2023, an estimated $411K.
  • Candriam SCA first reported a position in Aclaris Therapeutics in Q3 2022 and held it in 3 quarters.
  • Candriam SCA's Aclaris Therapeutics position peaked at $924K in Q4 2022.
  • 133 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2023.

Based on Candriam SCA's 13F filing for Q2 2023, filed 8 Aug 2023.